Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: June 2014

Chapter 43 - Traumatic brain injury

from Section 7 - Disease-specific neurorehabilitation systems

Related content

Powered by UNSILO


1. Brown AW, Elovic EP, Kothari S, et al. Congenital and acquired brain injury. 1. Epidemiology, pathophysiology, prognostication, innovative treatments, and prevention. Arch Phys Med Rehabil 2008; 89: S3–8.
2. Summers CR, Ivins B, Schwab KA. Traumatic brain injury in the United States: an epidemiologic overview. Mt Sinai J Med 2009; 76: 105–10.
3. Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010; 25: 72–80.
4. DePalma RG, Burris DG, Champion HR, et al. Blast injuries. N Engl J Med 2005; 352: 1335–42.
5. Martin EM, Lu WC, Helmick K, et al. Traumatic brain injuries sustained in the Afghanistan and Iraq wars. Am J Nurs 2008; 108: 40–7.
6. Dardiotis E, Fountas KN, Dardioti M, et al. Genetic association studies in patients with traumatic brain injury. Neurosurg Focus 2010; 28: E9.
7. Jordan BD. Genetic influences on outcome following traumatic brain injury. Neurochem Res 2007; 32: 905–15.
8. Pelinka LE, Kroepfl A, Leixnering M, et al. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004; 21: 1553–61.
9. Berger RP, Adelson PD, Pierce MC, et al. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 2005; 103: 61–8.
10. Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 1998; 273: 22490–7.
11. Svetlov SI, Larner SF, Kirk DR, et al. Biomarkers of blast-induced neurotrauma: profiling molecular and cellular mechanisms of blast brain injury. J Neurotrauma 2009; 26: 913–21.
12. Bazarian JJ, Blyth B, Cimpello L. Bench to bedside: evidence for brain injury after concussion–looking beyond the computed tomography scan. Acad Emerg Med 2006; 13: 199–214.
13. Dubroff JG, Newberg A. Neuroimaging of traumatic brain injury. Semin Neurol 2008; 28: 548–57.
14. De Coene B, Hajnal JV, Pennock JM, et al. MRI of the brain stem using fluid attenuated inversion recivery pulse sequences. Neuroradiology 1993; 35: 327–31.
15. Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, Part 1. Am J Neuroradiol 2009; 30: 19–30.
16. Kou Z, Wu Z, Tong KA, et al. The role of advanced MR imaging findings as biomarkers of traumatic brain injury. J Head Trauma Rehabil 2010; 25: 267–82.
17. Tong KA, Ashwal S, Holshouser BA, et al. Hemorrhagic shearing lesions in children and adolescents with posttraumatic diffuse axonal injury: improved detection and initial results. Radiology 2003; 227: 332–9.
18. Wu Z, Li S, Lei J, et al. Evaluation of traumatic subarachnoid hemorrhage using susceptibility-weighted imaging. Am J Neuroradiol 2010; 31: 1302–10.
19. Ptak T, Sheridan RL, Rhea JT, et al. Cerebral fractional anisotropy score in trauma patients: a new indicator of white matter injury after trauma. Am J Roentgenol 2003; 181: 1401–7.
20. Ross BD, Ernst T, Kreis R, et al. 1H MRS in acute traumatic brain injury. J Magn Reson Imaging 1998; 8: 829–40.
21. Garnett MR, Blamire AM, Rajagopalan B, et al. Evidence for cellular damage in normal-appearing white matter correlates with injury severity in patients following traumatic brain injury: a magnetic resonance spectroscopy study. Brain 2000; 123: 1403–9.
22. Garnett MR, Corkill RG, Blamire AM, et al. Altered cellular metabolism following traumatic brain injury: a magnetic resonance spectroscopy study. J Neurotrauma 2001; 18: 231–40.
23. Ashwal S, Holshouser BA, Tong KA. Use of advanced neuroimaging techniques in the evaluation of pediatric traumatic brain injury. Dev Neurosci 2006; 28: 309–26.
24. Makoroff KL, Cecil KM, Care M, et al. Elevated lactate as an early marker of brain injury in inflicted traumatic brain injury. Pediatr Radiol 2005; 35: 668–76.
25. Alavi A, Mirot A, Newberg A, et al. Fluorine-18-FDG evaluation of crossed cerebellar diaschisis in head injury. J Nucl Med 1997; 38: 1717–20.
26. Teasdale GM, Murray GD, Nicoll JA. The association between APOE epsilon4, age and outcome after head injury: a prospective cohort study. Brain 2005; 128: 2556–61.
27. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19–52.
28. Ariza M, Matarin MD, Junque C, et al. Influence of angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury. J Neuropsychiatry Clin Neurosci 2006; 18: 39–44.
29. Martinez-Lucas P, Moreno-Cuesta J, Garcia-Olmo DC, et al. Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury. Intensive Care Med 2005; 31: 1168–73.
30. Uzan M, Tanriverdi T, Baykara O, et al. Association between interleukin-1 beta (IL-1beta) gene polymorphism and outcome after head injury: an early report. Acta Neurochir 2005; 147: 715–20.
31. Hadjigeorgiou GM, Paterakis K, Dardiotis E, et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury. Neurology 2005; 65: 1077–82.
32. Chiaretti A, Antonelli A, Mastrangelo A, et al. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma 2008; 25: 225–34.
33. Chew E, Zafonte RD. Pharmacological management of neurobehavioral disorders following traumatic brain injury–a state-of-the-art review. J Rehabil Res Dev 2009; 46: 851–79.
34. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001; 344: 556–63.
35. Clifton GL, Choi SC, Miller ER, et al. Intercenter variance in clinical trials of head trauma–experience of the National Acute Brain Injury Study: Hypothermia. J Neurosurg 2001; 95: 751–5.
36. Hutchison JS, Ward RE, Lacroix J, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008; 358: 2447–56.
37. Talving P, Lustenberger T, Kobayashi L, et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 2010; 251: 1–4.
38. Stahel PF, Flierl MA. Erythropoietin in traumatic brain injury: the “golden bullet” on the horizon? Neurol India 2009; 57: 693–4.
39. Lu D, Mahmood A, Qu C, et al. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 2005; 22: 1011–17.
40. Mammis A, McIntosh TK, Maniker AH. Erythropoietin as a neuroprotective agent in traumatic brain injury: review. Surg Neurol 2009; 71: 527–31.
41. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49: 391–402.
42. Zafonte R, Friedewald WT, Lee SM, et al. The citicoline brain injury treatment (COBRIT) trial: design and methods. J Neurotrauma 2009; 26: 2207–16.
43. Dempsey RJ, Raghavendra Rao VL. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J Neurosurg 2003; 98: 867–73.
44. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002; 33: 2850–7.
45. Yurkewicz L, Weaver J, Bullock MR, et al. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 2005; 22: 1428–43.
46. Maas AI, Murray G, Henney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006; 5: 38–45.
47. Martin RT, Whyte J. The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness: a meta-analysis of n-of-1 studies. Am J Phys Med Rehabil 2007; 86: 613–20.
48. Meythaler JM, Brunner RC, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002; 17: 300–13.
49. Hughes S, Colantonio A, Santaguida PL, et al. Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury. Brain Inj 2005; 19: 1197–206.
50. Patrick PD, Blackman JA, Mabry JL, et al. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol 2006; 21: 879–85.
51. Teitelman E. Off-label uses of modafinil. Am J Psychiatry 2001; 158: 1341.
52. Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil 2008; 23: 52–63.
53. Gualtieri CT, Evans RW. Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. Brain Inj 1988; 2: 273–90.
54. Plenger PM, Dixon CE, Castillo RM, et al. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 1996; 77: 536–40.
55. Whyte J, Hart T, Vaccaro M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil 2004; 83: 401–20.
56. Reid WM, Hamm RJ. Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury. J Neurotrauma 2008; 25: 248–56.
57. Ripley DL. Atomoxetine for individuals with traumatic brain injury. J Head Trauma Rehabil 2006; 21: 85–8.
58. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997; 9: 222–30.
59. Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent Nerv Syst Trauma 1986; 3: 333–42.
60. Cardenas DD, McLean A, Farrell-Roberts L, et al. Oral physostigmine and impaired memory in adults with brain injury. Brain Inj 1994; 8: 579–87.
61. Silver JM, Koumaras B, Chen M, et al. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology 2006; 67: 748–55.
62. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004; 85: 1050–5.
63. Riggio S, Wong M. Neurobehavioral sequelae of traumatic brain injury. Mt Sinai J Med 2009; 76: 163–72.
64. Lieberman SA, Oberoi AL, Gilkison CR, et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J Clin Endocr Metab 2001; 86: 2752–6.
65. Bondanelli M, De Marinis L, Ambrosio MR, et al. Occurrence of pituitary dysfunction following traumatic brain injury. J Neurotrauma 2004; 21: 685–96.
66. Schneider M, Schneider HJ, Stalla GK. Anterior pituitary hormone abnormalities following traumatic brain injury. J Neurotrauma 2005; 22: 937–46.
67. Ceballos R. Pituitary changes in head trauma (analysis of 102 consecutive cases of head injury). Ala J Med Sci 1966; 3: 185–98.
68. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993; 34: 216–22.
69. Daniel PM, Prichard MM, Treip CS. Traumatic infarction of the anterior lobe of the pituitary gland. Lancet 1959; 2: 927–31.
70. Kornblum RN, Fisher RS. Pituitary lesions in craniocerebral injuries. Arch Path Lab Med 1969; 88: 242–8.
71. Popovic V, Pekic S, Pavlovic D, et al. Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. J Endocrinol Invest 2004; 27: 1048–54.
72. Aimaretti G, Ambrosio MR, Benvenga S, et al. Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). Growth Horm IGF Res 2004; 14: S114–17.
73. Kelly DF, Gonzalo IT, Cohan P, et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J Neurosurg 2000; 93: 743–52.
74. Benvenga S, Campenni A, Ruggeri RM, et al. Clinical review 113: hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 2000; 85: 1353–61.
75. Casanueva FF, Leal A, Koltowska-Haggstrom M, et al. Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: a KIMS-based study. Arch Phys Med Rehabil 2005; 86: 463–8.
76. Agha A, Phillips J, O'Kelly P, et al. The natural history of post-traumatic hypopituitarism: implications for assessment and treatment. Am J Med 2005; 118: 1416.
77. Agha A, Thornton E, O'Kelly P, et al. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab 2004; 89: 5987–92.
78. Bavisetty S, McArthur DL, Dusick JR, et al. Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. Neurosurgery 2008; 62: 1080–93.
79. Park KD, Kim DY, Lee JK, et al. Anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury patients and the influence on functional outcome. Brain Inj 2010; 24: 1330–5.
80. High WM, Briones-Galang M, Clark JA, et al. Effect of growth hormone replacement therapy on cognition after traumatic brain injury. J Neurotrauma 2010; 27: 1565–75.
81. Springer J, Chollet A. A traumatic car crash. Lancet 2001; 357: 1848.
82. Ghigo E, Masel B, Aimaretti G, et al. Consensus guidelines on screening for hypopituitarism following traumatic brain injury. Brain Inj 2005; 19: 711–24.
83. Katz RT, Brander V, Sahgal V. Updates on the diagnosis and management of posttraumatic hydrocephalus. Am J Phys Med Rehabil 1989; 68: 91–6.
84. Zasler NKD, Zafonte R. Brain Injury Medicine: Principles and Practice. New York, NY: Demos, 2007.
85. Aminoff MGD, Simon R. Clinical Neurology. New York, NY: McGraw-Hill, 2005.
86. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71: 576–86.
87. Yablon SA. Posttraumatic seizures. Arch Phys Med Rehabil 1993; 74: 983–1001.
88. Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery 1990; 27: 1–11.
89. Payan H, Toga M, Berard-Badier M. The pathology of post-traumatic epilepsies. Epilepsia 1970; 11: 81–94.
90. Agrawal A, Timothy J, Pandit L, et al. Post-traumatic epilepsy: an overview. Clin Neurol Neurosurg 2006; 108: 433–9.
91. Temkin NR. Risk factors for posttraumatic seizures in adults. Epilepsia 2003; 44: 18–20.
92. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256–62.
93. Annegers JF, Grabow JD, Groover RV, et al. Seizures after head trauma: a population study. Neurology 1980; 30: 683–9.
94. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42: 515–24.
95. Chang BS, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 60: 10–16.
96. Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265: 1271–7.
97. Perna R. Brain injury: benzodiazepines, antipsychotics, and functional recovery. J Head Trauma Rehabil 2006; 21: 82–4.
98. Young RR. Spasticity: a review. Neurology 1994; 44: S12–20.
99. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–7.
100. Ansari NN, Naghdi S, Hasson S, et al. The Modified Tardieu Scale for the measurement of elbow flexor spasticity in adult patients with hemiplegia. Brain Inj 2008; 22: 1007–12.
101. Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand 2010; 190: 62–6.
102. Tan J. Practice Manual of Physical Medicine and Rehabilitation. St Louis, MO: Mosby, 1998.
103. Kaplan FS, Glaser DL, Hebela N, et al. Heterotopic ossification. J Am Acad Orthop Surg 2004; 12: 116–25.
104. Watanabe TKSM. Common medical complications of traumatic brain injury. Phys Med Rehabil 2001; 15: 283–99.
105. Van den Bossche L, Van der Straeten G. Heterotopic ossification: a review. J Rehabil Med 2005; 37: 129–36.
106. Blackman JA, Patrick PD, Buck ML, et al. Paroxysmal autonomic instability with dystonia after brain injury. Arch Neurol 2004; 61: 321–8.
107. Baguley IJ, Cameron ID, Green AM, et al. Pharmacological management of dysautonomia following traumatic brain injury. Brain Inj 2004; 18: 409–17.
108. Bullard DE. Diencephalic seizures: responsiveness to bromocriptine and morphine. Ann Neurol 1987; 21: 609–11.
109. Wang VY, Manley G. Recognition of paroxysmal autonomic instability with dystonia (PAID) in a patient with traumatic brain injury. J Trauma 2008; 64: 500–2.
110. McAllister TW. Neurobehavioral sequelae of traumatic brain injury: evaluation and management. World Psychiatry 2008; 7: 3–10.
111. Tsaousides T, Gordon WA. Cognitive rehabilitation following traumatic brain injury: assessment to treatment. Mt Sinai J Med 2009; 76: 173–81.
112. McCrea M, Guskiewicz KM, Marshall SW, et al. Acute effects and recovery time following concussion in collegiate football players: the NCAA concussion study. JAMA 2003; 290: 2556–63.
113. Ruttan L, Martin K, Liu A, et al. Long-term cognitive outcome in moderate to severe traumatic brain injury: a meta-analysis examining timed and untimed tests at 1 and 4.5 or more years after injury. Arch Phys Med Rehabil 2008; 89: S69–76.
114. Sandel ME, Mysiw WJ. The agitated brain injured patient. Part 1: Definitions, differential diagnosis, and assessment. Arch Phys Med Rehabil 1996; 77: 617–23.
115. Nott MT, Chapparo C, Baguley IJ. Agitation following traumatic brain injury: an Australian sample. Brain Inj 2006; 20: 1175–82.
116. Rogers JM, Read CA. Psychiatric comorbidity following traumatic brain injury. Brain Inj 2007; 21: 1321–33.
117. Whelan-Goodinson R, Ponsford J, Johnston L, et al. Psychiatric disorders following traumatic brain injury: their nature and frequency. J Head Trauma Rehabil 2009; 24: 324–32.
118. Simpson G, Tate R. Suicidality in people surviving a traumatic brain injury: prevalence, risk factors and implications for clinical management. Brain Inj 2007; 21: 1335–51.
119. King NS. PTSD and traumatic brain injury: folklore and fact? Brain Inj 2008; 22: 1–5.
120. van Reekum R, Cohen T, Wong J. Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci 2000; 12: 316–27.
121. Minderhoud JM, Boelens ME, Huizenga J, et al. Treatment of minor head injuries. Clin Neurol Neurosurg 1980; 82: 127–40.
122. Baandrup L, Jensen R. Chronic post-traumatic headache–a clinical analysis in relation to the International Headache Classification, 2nd edition. Cephalalgia 2005; 25: 132–8.
123. Evans RW. Post-traumatic headaches. Neurol Clin 2004; 22: 237–49.
124. Packard RC. Epidemiology and pathogenesis of posttraumatic headache. J Head Trauma Rehabil 1999; 14: 9–21.
125. Bushnik T, Englander J, Wright J. The experience of fatigue in the first 2 years after moderate-to-severe traumatic brain injury: a preliminary report. J Head Trauma Rehabil 2008; 23: 17–24.
126. Ouellet MC, Savard J, Morin CM. Insomnia following traumatic brain injury: a review. Neurorehabil Neural Repair 2004; 18: 187–98.
127. Chen H, Epstein J, Stern E. Neural plasticity after acquired brain injury: evidence from functional neuroimaging. PM R 2010; 2: S306–12.
128. Weiller C, Chollet F, Friston KJ, et al. Functional reorganization of the brain in recovery from striatocapsular infarction in man. Ann Neurol 1992; 31: 463–72.
129. Werring DJ, Clark CA, Barker GJ, et al. The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule. J Neurol Neurosurg Psychiatry 1998; 65: 863–9.
130. Nakamura T, Hillary FG, Biswal BB. Resting network plasticity following brain injury. PloS One 2009; 4: e8220.
131. Ween JE. Functional imaging of stroke recovery: an ecological review from a neural network perspective with an emphasis on motor systems. J Neuroimaging 2008; 18: 227–36.
132. Swaine BR, Sullivan SJ. Longitudinal profile of early motor recovery following severe traumatic brain injury. Brain Inj 1996; 10: 347–66.
133. Page S, Levine P. Forced use after TBI: promoting plasticity and function through practice. Brain Inj 2003; 17: 675–84.
134. Page SJ, Yablon S. Plasticity in TBI: concepts and applications. Brain Inj 2003; 17: 639–41.